H.C. Wainwright Reiterates Their Buy Rating on Awakn Life Sciences (AWKNF)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Awakn Life Sciences (AWKNFResearch Report), with a price target of $10.00. The company’s shares closed last Wednesday at $0.35, equals to its 52-week low of $0.35.

According to, Trucchio is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.6% and a 30.6% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Awakn Life Sciences is a Moderate Buy with an average price target of $8.10.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $2.71 and a one-year low of $0.35. Currently, Awakn Life Sciences has an average volume of 5,576.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AWKNF in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Awakn Life Sciences Corp is a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction.

Read More on AWKNF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More